GlassScriptPhysician profile
Emily G Magee
NPI 1306102793
$2,433.18
in general payments reported to CMS, 2019-2025
29 companies · $518 in 2025
The $518 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $109 · 2021: $600 · 2022: $352 · 2023: $268 · 2024: $161 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $652.04 | 2019-2021 | |
| Astellas Pharma US INC | $398.04 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $272.48 | 2019-2023 | |
| Pfizer INC. | $140.19 | 2020-2025 | |
| Avion Pharmaceuticals | $129.91 | 2019-2023 | Balcoltra |
| Organon LLC | $85.55 | 2023-2024 | Jada System, Nexplanon |
| Exeltis, USA INC. | $76.45 | 2019-2025 | Slynd |
| Myriad Genetic Laboratories, INC. | $67.94 | 2020 | |
| Coopersurgical, INC. | $64.45 | 2019-2025 | Paragard T 380a, Sos |
| Therapeuticsmd, INC. | $60.32 | 2019-2022 | |
| Millicent US INC | $52.04 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Mayne Pharma Commercial LLC | $51.56 | 2025 | |
| Duchesnay USA Incorporated | $48.96 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.92 | 2019 | |
| Dilon Technologies, INC. | $36.77 | 2025 | Hemoblast Bellows |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.12 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $30.22 | 2019-2025 | |
| Hologic Sales and Service, LLC | $29.91 | 2024 | Affirm Prone Biopsy System |
| Sage Therapeutics, LLC | $19.30 | 2023 | |
| Scynexis, INC. | $19.10 | 2022 | |
| Biogen, INC. | $17.66 | 2019 | |
| Agile Therapeutics, INC. | $16.39 | 2022 | |
| Evofem Biosciences, INC. | $15.89 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.04 | 2023 | Exparel |
| Meditrina | $13.95 | 2025 | |
| Medtronic, INC. | $13.79 | 2022 | |
| Merck Sharp & Dohme LLC | $12.40 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.51 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.